Thursday, 26 May 2022
WorldPfizer's Covid-19 pill questioned due to relapsed cases

Pfizer’s Covid-19 pill questioned due to relapsed cases

It was emphasized that US doctors and health officials had doubts about the functionality of Pfizer’s Paxlovid pill, which can be used at home against Covid-19, as a result of the reappearance of virus symptoms in some of the users.

Experts who conducted research on 1,000 adults using Paxlovid reportedly thought “there is still a lot to learn” about the drug, which was released with permission for use by adults at high risk of severe Covid-19.

While the doctors in the research team talked about the presence of cases with Covid-19 symptoms recurring a few days after completing the five-day intake of Paxlovid, they expressed that they were not sure whether the virus in these patients was still contagious and whether they should receive a second course of Paxlovid.

The opinion of Andy Pekosz from Johns Hopkins University was also included that “the dose of Paxlovid may not be strong enough to completely suppress the virus and may trigger drug-resistant mutations.”

Last week, the Food and Drug Administration (FDA) reported that it “has no evidence” that Pfizer’s Covid-19 pill is beneficial to patients who have re-infected it.

The US government had purchased Paxlovid pills from Pfizer to treat 20 million people, and paid the pharmaceutical company more than $10 billion for it.

., . . (HAS) .. ..

Popular content

Latest article

More article